Neoplasm of esophagus

Summary

Neoplasm of esophagus (MONDO:0021355) is a cancer (an umbrella term covering 5 Mondo subtypes) and 212 clinical trials. Top therapeutic interventions include fondaparinux, irinotecan, and octreotide. A subtype of esophageal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 212

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neoplasm of esophagus
Mondo ID	MONDO:0021355
NCIT	C3028
SNOMED CT	126817006
UMLS	C0014859
MedGen	4547
Anatomy (UBERON)	UBERON:0001043
Is cancer (heuristic)	yes

Also known as: esophageal neoplasm · esophageal neoplasms, benign and malignant · esophageal tumor · esophageal tumors · esophageal tumour · esophageal tumours · esophagus neoplasm · esophagus neoplasm (disease) · esophagus tumor · neoplasm of esophagus · neoplasm of the esophagus · neoplasm of the oesophagus · oesophagus neoplasm · oesophagus neoplasm (disease) · oesophagus tumour · tumor of esophagus · tumor of the esophagus · tumour of oesophagus · tumour of the oesophagus

Disease family

This is a subtype of esophageal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › upper digestive tract disorder › esophageal disorder › neoplasm of esophagus

Related subtypes (19): esophageal atresia, esophageal varices, esophagitis, megaesophagus, esophageal tuberculosis, esophageal leukoplakia, dyskinesia of esophagus, esophageal diverticulosis, gastroesophageal reflux disease, esophageal atresia/tracheoesophageal fistula, achalasia, Barrett esophagus, esophageal duplication cyst, tubular duplication of the esophagus, laryngotracheoesophageal cleft, isolated tracheo-esophageal fistula, congenital esophageal diverticulum, esophageal ulcer, congenital esophageal stenosis

Subtypes (5): esophageal granular cell tumor, esophageal neuroendocrine tumor, neurofibroma of the esophagus, esophageal cancer, benign neoplasm of esophagus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 212.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	110
PHASE2	52
PHASE3	17
PHASE1/PHASE2	14
PHASE1	11
PHASE4	7
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02558504	PHASE4	COMPLETED	Radiofrequency in the Treatment of Barrett’s Oesophagus
NCT02721550	PHASE4	TERMINATED	A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC
NCT02721563	PHASE4	COMPLETED	A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC
NCT02721576	PHASE4	TERMINATED	A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC
NCT05067153	PHASE4	UNKNOWN	Thromboprophylaxis in Oesophageal Cancer Patients
NCT05688020	PHASE4	UNKNOWN	Tranexamic Acid During Upper GI Endoscopic Resection Procedures
NCT05768282	PHASE4	UNKNOWN	Oral Prednisolone to Prevent Esophageal Stricture After RFA for Long-segment Esophageal Neoplasia
NCT04513418	PHASE3	RECRUITING	Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
NCT06086457	PHASE3	RECRUITING	PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
NCT00190554	PHASE3	TERMINATED	A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma
NCT00559351	PHASE3	TERMINATED	RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
NCT00653107	PHASE3	TERMINATED	Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only
NCT00760604	PHASE3	TERMINATED	A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer
NCT01726452	PHASE3	COMPLETED	NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
NCT01745107	PHASE3	UNKNOWN	Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;
NCT01911832	PHASE3	UNKNOWN	Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers
NCT02279134	PHASE2/PHASE3	UNKNOWN	Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma
NCT02319187	PHASE3	UNKNOWN	Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial
NCT02395705	PHASE3	COMPLETED	Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
NCT02604615	PHASE3	UNKNOWN	The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy
NCT02845479	PHASE3	COMPLETED	The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I
NCT02891083	PHASE3	UNKNOWN	Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer
NCT03189719	PHASE3	COMPLETED	First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
NCT03308552	PHASE3	UNKNOWN	Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02
NCT03881111	PHASE3	WITHDRAWN	First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
NCT05176002	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
NCT05252078	PHASE2	RECRUITING	Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
NCT05624099	PHASE2	RECRUITING	Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
NCT05944237	PHASE1/PHASE2	RECRUITING	HTL0039732 in Participants With Advanced Solid Tumours
NCT06084897	PHASE2	RECRUITING	Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
NCT06380816	PHASE1/PHASE2	RECRUITING	A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
NCT06445972	PHASE1/PHASE2	RECRUITING	Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06469944	PHASE1/PHASE2	RECRUITING	Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06643689	PHASE2	NOT_YET_RECRUITING	Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms
NCT06646588	PHASE2	RECRUITING	Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
NCT00037089	PHASE2	UNKNOWN	A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer
NCT00041808	PHASE1/PHASE2	COMPLETED	Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
NCT00042510	PHASE2	COMPLETED	Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
NCT00048529	PHASE2	SUSPENDED	Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus
NCT00054873	PHASE2	COMPLETED	Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FONDAPARINUX	4	3
IRINOTECAN	4	3
OCTREOTIDE	4	2
PEMBROLIZUMAB	4	2
AMIVANTAMAB	4	1
DALTEPARIN SODIUM	4	1
EPINEPHRINE	4	1
EPIRUBICIN	4	1
FERUMOXYTOL	4	1
FISH OIL TRIGLYCERIDES	4	1
FRUQUINTINIB	4	1
INDOMETHACIN	4	1
ITRACONAZOLE	4	1
LENVATINIB	4	1
LEVOLEUCOVORIN	4	1
NADROPARIN CALCIUM	4	1
NITROGLYCERIN	4	1
PLICAMYCIN	4	1
POVIDONE-IODINE	4	1
REGORAFENIB	4	1
ROMIDEPSIN	4	1
NEDAPLATIN	3	2
ALVOCIDIB	3	1
BEMIPARIN SODIUM	3	1
BENMELSTOBART	3	1
CAMRELIZUMAB	3	1
CATEQUENTINIB HYDROCHLORIDE	3	1
ENTINOSTAT	3	1
LITHIUM	3	1
NIMOTUZUMAB	3	1